Remote ECG monitoring after TAVI

Remote ECG Monitoring as a Diagnostic Tool for Therapeutic Strategies After Transcatheter Aortic Valve Replacement: Rationale and Design of the DRAGON-TAVI Trial.

Not applicable Interventional Medical University of Silesia · NCT07521800

This compares continuous 30-day remote ECG monitoring to standard short-term monitoring for adults after TAVI to see if it detects rhythm problems earlier.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment250 (estimated)
Ages18 Years and up
SexAll
SponsorMedical University of Silesia Academic / other
Locations4 sites (Turin and 3 other locations)
Trial IDNCT07521800 on ClinicalTrials.gov

What this trial studies

The DRAGON TAVI trial is a multicenter, prospective, open-label, randomized 1:1 trial enrolling 250 adults undergoing transcatheter aortic valve implantation (TAVI). Participants are assigned to either continuous 30-day remote ECG monitoring with visits triggered by abnormal ECG findings or to standard care consisting of 24–48 hour post‑op ECG monitoring plus a routine ECG within 30 days. The study follows patients for approximately 12 months to capture new atrial fibrillation, atrioventricular block, and clinically relevant events leading to intervention. Key exclusions include prior atrial fibrillation/flutter, known conduction disturbances, and presence of pacemaker/ICD devices.

Who should consider this trial

Good fit: Adults over 18 with severe aortic stenosis judged moderate or high cardiovascular risk by a Heart Team and scheduled for TAVI who give informed consent and have no prior AF/flutter or implanted pacing/defibrillator devices.

Not a fit: Patients with a history of atrial fibrillation/flutter, known conduction disorders, existing pacemaker/ICD, or those unable to use remote monitoring technology are unlikely to benefit from this approach.

Why it matters

Potential benefit: If successful, earlier detection of post‑TAVI arrhythmias could allow faster treatment and may reduce complications and unplanned hospital visits.

How similar studies have performed: Similar extended or remote ECG monitoring approaches have increased detection of post‑procedure arrhythmias in other settings, but continuous 30‑day remote monitoring after TAVI is not yet established as standard care.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patient age over 18 years old
* Severe aortic stenosis
* Moderate or high cardiovascular risk based on current ESC Guidelines "Heart Team" qualification for TAVI
* Written informed consent of the patient for participation in the study

Exclusion Criteria:

* History of atrial fibrillation or atrial flutter
* Previously known conduction disturbances\*\*
* Presence of: pacemaker, CRT-P, ICD, CRT-D before or after TAVI
* Ischaemic stroke, TIA, MI or heart surgery within 1 month before TAVI qualification
* Haemorrhagic stroke within 1 year before TAVI qualification
* Chronic immunosuppressive therapy
* Comorbidities (e.g. drug addiction, alcohol abuse, emotional/mental disorders) which do not allow safe participation in the study

Where this trial is running

Turin and 3 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions TAVIRemote MonitoringArrythmiaAtrial FibrillationAtrioventricular BlockECGMonitoring
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.